Praliciguat
As of the edition of 20 October 2026, Praliciguat is a small molecule: in active development; acts on GUCY1A1, GUCY1A2 and GUCY1B1 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 8, 0 stopped early
- Disease areas
- Heart and blood vessels; Hormones; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 5 | 4 | 1 | 0 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cyclerion Therapeutics | Lead sponsor of trials | 2015 to now |
| Akebia Therapeutics | Lead sponsor of trials | 2017 to now |